Description General description A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC50 = 800 nM). A rolipram-insensitive PDE IV subtype is also known to exist. Also inhibits NF-κB and NFAT activation in Jurkat and primary T cells. Cell permeable, selective competitive inhibitor of cAMP-specific phosphodiesterase IV (IC50 = 800 nM). Rolipram does not inhibit PDE I or PDE II, even at concentrations as high as 100 µM. It is only a weak inhibitor of PDE III (IC50 = 100 µM). A rolipram-insensitive phosphodiesterase IV subtype is also known to exist. Packaging 5 mg in Plastic ampoule Biochem/physiol Actions Cell permeable: yes Primary Target PDE IV Product does not compete with ATP. Reversible: no Target IC50: 800 nM against cAMP-specific phosphodiesterase (PDE IV) Warning Toxicity: Irritant (B) Reconstitution Following reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 6 months at -20°C. Other Notes Navarro, J., et al. 1998. J. Virol. 72, 4712. Truong, V.H. and Muller, T. 1994. FEBS Lett.353, 113. Underwood, D.C., et al. 1994. J. Pharmacol. Exp. Ther. 270, 250. Moore, J.B., Jr., et al. 1991. Biochem. Pharmacol.42, 679. Reeves, M.L., et al. 1987. Biochem. J. 241, 535. Schneider, H.H., et al. 1986. Eur. J. Pharmacol.127, 105.